217 completed, 13 recruiting, 10 unknown, 8 terminated. 259 Phase 1, 1 Phase 2.
By phase and status
Follow Hepatic Impairment: new trials by email Literature Review of Hepatic Impairment trials Research Report on Hepatic Impairment
Trials (filtered) newest first · largest first
All 259 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Tacabrutideg (BGB-16673) in Participants With Moderate and Severe Hepatic Impairment Tacabrutideg - Hepatic Impairment, Healthy Adult Participants | Phase 1 | Not yet recruiting | 24 | 2026-12-01 | 2026-11-04 |
Pharmacokinetics of Engasertib in Participants With and Without Hepatic Impairment Engasertib - Hepatic Impairment | Phase 1 | Not yet recruiting | 18 | 2026-12-01 | 2026-11-16 |
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Sonrotoclax in Participants With Severe Hepatic Impairment Sonrotoclax - Hepatic Impairment, Healthy Adult Participants | Phase 1 | Not yet recruiting | 12 | 2026-11-01 | 2026-10-20 |
Aleniglipron Hepatic Impairment Study Aleniglipron - Hepatic Impairment | Phase 1 | Not yet recruiting | 36 | 2026-10-01 | 2026-10-21 |
A Phase I Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD4144 AZD4144 - Hepatic Impairment | Phase 1 | Not yet recruiting | 30 | 2026-08-24 | 2026-08-24 |
Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function Casdatifan - Healthy Participants, Hepatic Impairment | Phase 1 | Recruiting | 16 | 2026-08-14 | 2026-09-04 |
A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment Treprostinil Palmitil Inhalation Powder - Hepatic Impairment | Phase 1 | Recruiting | 30 | 2026-07-14 | 2026-11-09 |
A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease Atirmociclib - Hepatic Impairment, Healthy, Hepatic Insufficiency | Phase 1 | Recruiting | 28 | 2026-06-29 | 2026-08-21 |
A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems BI 3000202 - Healthy, Hepatic Impairment | Phase 1 | Completed | 34 | 2026-05-01 | 2026-11-12 |
MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function Midomafetamine HCl - Pharmacokinetics, Hepatic Impairment | Phase 1 | Not yet recruiting | 16 | 2026-03-29 | 2024-10-30 |
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234 AZD6234, AZD9550 - Hepatic Impairment | Phase 1 | Recruiting | 28 | 2026-03-20 | 2026-10-22 |
Radiprodil in Participants With Hepatic Impairment Radiprodil - Hepatic Impairment | Phase 1 | Recruiting | 40 | 2026-03-03 | 2026-05-08 |
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function PF-07328948 - Hepatic Impairment, Healthy | Phase 1 | Recruiting | 26 | 2025-12-22 | 2026-07-23 |
A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment BMS-986435 - Healthy Volunteers, Hepatic Impairment | Phase 1 | Completed | 69 | 2025-12-15 | 2026-09-21 |
A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017) Calderasib - Healthy, Hepatic Impairment | Phase 1 | Completed | 32 | 2025-11-05 | 2026-08-04 |
A Clinical Study of MK-8527 in Participants With Mild and Moderate Hepatic Impairment (MK-8527-015) MK-8527 - Hepatic Impairment, Healthy Participants | Phase 1 | Completed | 18 | 2025-09-19 | 2026-02-27 |
Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls BPN14770 - Hepatic Impairment | Phase 1 | Completed | 32 | 2025-08-30 | 2026-02-27 |
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib Inavolisib - Hepatic Impairment | Phase 1 | Completed | 27 | 2025-08-21 | 2026-10-23 |
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems BI 1291583 - Healthy, Hepatic Impairment | Phase 1 | Recruiting | 32 | 2025-07-17 | 2026-10-13 |
Pharmacokinetics, Safety and Tolerability of ITF2357 in Participants With Chronic Hepatic Impairment and With Normal Hepatic Function ITF2357 - Hepatic Impairment | Phase 1 | Completed | 24 | 2025-05-29 | 2026-06-18 |
Showing 20 of 259. Sign in to see all of them.
Narrower conditions
Liver Diseases (14) · Lymphoma, Follicular (9) · Hepatic Insufficiency (5) · Non-alcoholic Fatty Liver Disease (5) · Liver Cirrhosis (4) · Renal Insufficiency (4) · Fibrosis (3) · HIV Infections (3) · Acquired Immunodeficiency Syndrome (2) · Hematologic Neoplasms (2) · Hepatitis C (2) · Neoplasms (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Atrial Fibrillation (1) · Breast Neoplasms (1)
Broader conditions
Digestive System Diseases (28) · Liver Diseases (15) · Neoplasms (14) · Immune System Diseases (13) · Pathological Conditions, Signs and Symptoms (12) · Hemic and Lymphatic Diseases (11) · Pathologic Processes (11) · Neoplasms by Histologic Type (10) · Immunoproliferative Disorders (9) · Lymphatic Diseases (9) · Lymphoma (9) · Lymphoma, Non-Hodgkin (9) · Lymphoproliferative Disorders (9) · Urogenital Diseases (9) · Female Urogenital Diseases (6)
Interventions
AT-511 (2) · Ritonavir (2) · ZD4054 (2) · binimetinib (2) · dolutegravir (2) · enasidenib (2) · fedratinib (2) · quizartinib (2) · saroglitazar (2) · seladelpar (2) · telotristat (2) · (2-methyl-4-(5-methyl-2-(4-trifluoromethyl-phenyl)-2H-(1,2,3)triazol-4-ylmethylsulfanyl)phenoxy)acetic acid (1) · (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol (1) · 1-(3-(2-(1-benzothiophen-5-yl) ethoxy) propyl)-3-azetidinol maleate (1) · 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid (1)
Sponsors
Novartis Pharmaceuticals (22) · AstraZeneca (14) · Pfizer (13) · Janssen Research & Development, LLC (10) · Bristol-Myers Squibb (8) · Merck Sharp & Dohme LLC (8) · Celgene (6) · Jiangsu HengRui Medicine Co., Ltd. (6) · Amgen (5) · Takeda (5) · Daiichi Sankyo (4) · AbbVie (3) · Astellas Pharma Global Development, Inc. (3) · Biogen (3) · Eisai Inc. (3)
Countries
United States (180) · Germany (24) · China (18) · Slovakia (13) · Czechia (10) · Hungary (7) · Bulgaria (6) · Poland (6) · Russia (6) · Belgium (5) · South Korea (4) · Spain (4) · France (3) · Italy (3) · Japan (3)
Results publications
PMID 21414193, PMID 23197081, PMID 24084213, PMID 24374856, PMID 25136024, PMID 25511105, PMID 25633714, PMID 25975934, PMID 26519231, PMID 27267254, PMID 27570245, PMID 27645244, PMID 27743502, PMID 28365033, PMID 28430430, PMID 29026685, PMID 30052269, PMID 30194585, PMID 30224193, PMID 31632000, PMID 32304015, PMID 32648303, PMID 32800532, PMID 33356019, PMID 33749838, PMID 33813736, PMID 34002356, PMID 34046915, PMID 34115385, PMID 34246461, PMID 34324028, PMID 35061234, PMID 36217101, PMID 36352054, PMID 36471222, PMID 36786053, PMID 36977960, PMID 37070852, PMID 37801266, PMID 37917289, PMID 38993026, PMID 39287964, PMID 39358661, PMID 39601078, PMID 39688408, PMID 39932678, PMID 40549341, PMID 40614122, PMID 40748778, PMID 41021771
NIH funding
2019 (5), 2015 (2), 2017 (2), 2018 (2), 2016 (1), 2023 (1)